Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Douglas Smith

Showing results (11-20 of 203) with videos related to

Pageof 21
Sort By:
Leukemia Research|July 26, 2011
Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitorsBrady L Stein, B Douglas Smith
Leukemia Research|March 28, 2006
Exploiting oxidative damage to overcome resistanceJudith E Karp, B Douglas Smith
Leukemia Research|May 3, 2005
Curing acute myelogenous leukemia: still a major challengeB Douglas Smith, Judith E Karp
Clinical Lymphoma & Myeloma|September 26, 2009
What are the endpoints of therapy for acute leukemias? Old definitions and new challengesB Douglas Smith, Judith E Karp
The American Journal of the Medical Sciences|April 28, 2011
Prognostically important molecular markers in cytogenetically normal acute myeloid leukemiaTara L Lin, B Douglas Smith
Leukemia & Lymphoma|March 26, 2015
Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantJoshua F Zeidner, B Douglas Smith
British Journal of Haematology|June 26, 2003
Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial'B Douglas Smith, Judith Karp, Philip Burke
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulationTing Bao, B Douglas Smith, Judith E Karp
Expert Review of Hematology|November 19, 2010
FLT3 inhibitors in acute myeloid leukemiaKhaled el-Shami, Richard M Stone, B Douglas Smith
Current Opinion in Oncology|April 13, 2004
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplantGreg R Angstreich, B Douglas Smith, Richard J Jones
Pageof 21

Showing results (11-20 of 203) with videos related to

Sort By:
Pageof 21
Leukemia Research|July 26, 2011
Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitorsBrady L Stein, B Douglas Smith
Leukemia Research|March 28, 2006
Exploiting oxidative damage to overcome resistanceJudith E Karp, B Douglas Smith
Leukemia Research|May 3, 2005
Curing acute myelogenous leukemia: still a major challengeB Douglas Smith, Judith E Karp
Clinical Lymphoma & Myeloma|September 26, 2009
What are the endpoints of therapy for acute leukemias? Old definitions and new challengesB Douglas Smith, Judith E Karp
The American Journal of the Medical Sciences|April 28, 2011
Prognostically important molecular markers in cytogenetically normal acute myeloid leukemiaTara L Lin, B Douglas Smith
Leukemia & Lymphoma|March 26, 2015
Optimizing the management of relapsed chronic myeloid leukemia post-allogeneic bone marrow transplantJoshua F Zeidner, B Douglas Smith
British Journal of Haematology|June 26, 2003
Response to 'comparison of "sequential" versus "standard" chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial'B Douglas Smith, Judith Karp, Philip Burke
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulationTing Bao, B Douglas Smith, Judith E Karp
Expert Review of Hematology|November 19, 2010
FLT3 inhibitors in acute myeloid leukemiaKhaled el-Shami, Richard M Stone, B Douglas Smith
Current Opinion in Oncology|April 13, 2004
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplantGreg R Angstreich, B Douglas Smith, Richard J Jones
Pageof 21